| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | John C Wood | |
| P2860 | cites work | Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia | Q79210187 |
| Does liver biopsy overestimate liver iron concentration? | Q79844720 | ||
| Haemochromatosis | Q80150361 | ||
| Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron | Q80372740 | ||
| Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis | Q81511486 | ||
| Measurement of liver iron overload: noninvasive calibration of MRI-R2* by magnetic iron detector susceptometer | Q82773729 | ||
| Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients | Q83142327 | ||
| Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection | Q86100306 | ||
| Identification of erythroferrone as an erythroid regulator of iron metabolism | Q28240988 | ||
| A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance | Q28293758 | ||
| mRNA regulation of cardiac iron transporters and ferritin subunits in a mouse model of iron overload | Q28384189 | ||
| Pancreatic iron and fat assessment by MRI-R2* in patients with iron overload diseases. | Q30853786 | ||
| Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan | Q33783224 | ||
| R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. | Q33907529 | ||
| Nutritional deficiencies in iron overloaded patients with hemoglobinopathies | Q33920978 | ||
| MRI detects myocardial iron in the human heart. | Q33921092 | ||
| Physiology and pathophysiology of iron cardiomyopathy in thalassemia | Q33944096 | ||
| Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. | Q33958448 | ||
| Cardiac iron across different transfusion-dependent diseases | Q33958560 | ||
| Quantitative assessment of iron in heart and liver phantoms using dual-energy computed tomography | Q33962247 | ||
| Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major | Q34331274 | ||
| Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. | Q34333701 | ||
| Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis | Q34476161 | ||
| Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. | Q34548257 | ||
| Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. | Q34571501 | ||
| The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes | Q34655580 | ||
| Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model | Q34731198 | ||
| Rapid monitoring of iron-chelating therapy in thalassemia major by a new cardiovascular MR measure: the reduced transverse relaxation rate | Q35112908 | ||
| Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia | Q35528614 | ||
| Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease | Q35631734 | ||
| MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients | Q35848072 | ||
| The role of endocytic pathways in cellular uptake of plasma non-transferrin iron | Q35930563 | ||
| Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. | Q36078676 | ||
| On T2* magnetic resonance and cardiac iron | Q36214874 | ||
| Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. | Q36343351 | ||
| Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy | Q36444526 | ||
| Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. | Q36532618 | ||
| Nuclear magnetic resonance imaging of experimentally induced liver disease | Q36591602 | ||
| Molecular control of iron transport | Q36710628 | ||
| Iron storage in human disease: Fractionation of hepatic and splenic iron into ferritin and haemosiderin with histochemical correlations | Q36722079 | ||
| The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages | Q36901914 | ||
| Longitudinal analysis of heart and liver iron in thalassemia major | Q36915941 | ||
| Concepts and goals in the management of transfusional iron overload. | Q36985140 | ||
| Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload | Q37158717 | ||
| R2* magnetic resonance imaging of the liver in patients with iron overload | Q37201858 | ||
| Pancreatic iron loading predicts cardiac iron loading in thalassemia major. | Q37414689 | ||
| Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major | Q37442375 | ||
| Labile iron in cells and body fluids: physiology, pathology, and pharmacology | Q38198634 | ||
| Use of magnetic resonance imaging to monitor iron overload | Q38234248 | ||
| Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. | Q38423854 | ||
| Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. | Q38435433 | ||
| Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice | Q41028963 | ||
| A decisional algorithm to start iron chelation in patients with beta thalassemia | Q42000881 | ||
| Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator | Q42461969 | ||
| History and current impact of cardiac magnetic resonance imaging on the management of iron overload | Q42754197 | ||
| Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial | Q42783336 | ||
| The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores | Q43084909 | ||
| Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease | Q43105651 | ||
| Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia | Q43227256 | ||
| Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major | Q43242677 | ||
| Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients | Q43274578 | ||
| Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. | Q43477831 | ||
| Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis | Q43747887 | ||
| Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association | Q43850131 | ||
| Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors | Q44597837 | ||
| Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections | Q44942521 | ||
| Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine | Q45101211 | ||
| Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance | Q45112312 | ||
| Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. | Q46041997 | ||
| Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats. | Q46210519 | ||
| R2 and R2* are equally effective in evaluating chronic response to iron chelation. | Q46385813 | ||
| Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform | Q46502128 | ||
| In vivo comparison of myocardial T1 with T2 and T2* in thalassaemia major | Q46692543 | ||
| Pituitary iron and volume imaging in healthy controls. | Q46781383 | ||
| Cardiac iron overload in sickle-cell disease | Q46804573 | ||
| Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major | Q46939101 | ||
| Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera | Q46973687 | ||
| Pituitary gland height evaluated by MR in patients with beta-thalassemia major: a marker of pituitary gland function | Q47194969 | ||
| Pituitary iron and volume predict hypogonadism in transfusional iron overload | Q48732425 | ||
| Pancreatic iron and glucose dysregulation in thalassemia major. | Q51364719 | ||
| Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. | Q51597353 | ||
| Regional and global pancreatic T*2 MRI for iron overload assessment in a large cohort of healthy subjects: normal values and correlation with age and gender. | Q51601037 | ||
| On using T2 to assess extrinsic magnetic field inhomogeneity effects on T2* measurements in myocardial siderosis in thalassemia. | Q51859471 | ||
| Theory of nonexponential NMR signal decay in liver with iron overload or superparamagnetic iron oxide particles. | Q52036938 | ||
| Hepatic iron concentration and total body iron stores in thalassemia major. | Q52075941 | ||
| Quantitative computed tomography assessment of transfusional iron overload. | Q53228927 | ||
| The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. | Q54597213 | ||
| Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress | Q55549576 | ||
| High nontransferrin bound iron levels and heart disease in thalassemia major | Q62018235 | ||
| Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning | Q70481935 | ||
| Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major | Q70520129 | ||
| Magnetic-susceptibility measurement of human iron stores | Q70522448 | ||
| Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy | Q71228819 | ||
| Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods | Q71437370 | ||
| Variability in hepatic iron concentration measurement from needle-biopsy specimens | Q71701182 | ||
| Survival in medically treated patients with homozygous beta-thalassemia | Q72098000 | ||
| Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies | Q72291587 | ||
| Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging | Q72837057 | ||
| T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major | Q73220988 | ||
| Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases | Q73252070 | ||
| Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia | Q73426874 | ||
| The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation | Q73708500 | ||
| Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register | Q73966490 | ||
| Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload | Q77820142 | ||
| Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin | Q78198074 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 15-28 | |
| P577 | publication date | 2015-03-12 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Estimating tissue iron burden: current status and future prospects | |
| P478 | volume | 170 |
| Q38607875 | A complicated disease: what can be done to manage thalassemia major more effectively? |
| Q46522688 | Can hydroxyurea serve as a free radical scavenger and reduce iron overload in β-thalassemia patients? |
| Q39179797 | Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care |
| Q88273092 | Haemochromatosis |
| Q36162957 | Heart Rate Variability for Early Detection of Cardiac Iron Deposition in Patients with Transfusion-Dependent Thalassemia |
| Q39179372 | How we manage iron overload in sickle cell patients |
| Q37213466 | Increased mitochondrial DNA deletions and copy number in transfusion-dependent thalassemia |
| Q91654887 | Inherited iron overload disorders |
| Q98178909 | Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk |
| Q38727988 | Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? |
| Q41050245 | Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancer |
| Q92567341 | Iron intake, body iron status, and risk of breast cancer: a systematic review and meta-analysis |
| Q47805142 | Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment |
| Q48371193 | Lack of correlation between heart, liver and pancreas MRI-R2*: Results from long-term follow-up in a cohort of adult β-thalassemia major patients |
| Q89647038 | Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies |
| Q38836181 | Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? |
| Q38631586 | Optimizing the diagnosis and the treatment of iron overload diseases |
| Q87850067 | Quantitative susceptibility mapping in combination with water-fat separation for simultaneous liver iron and fat fraction quantification |
| Q42373908 | Renal iron accumulation occurs in lupus nephritis and iron chelation delays the onset of albuminuria |
| Q48099529 | Serum ferritin in the diagnosis of cardiac and liver iron overload in thalassaemia patients real-world practice: a multicentre study. |
| Q38569638 | Thalassaemia in children: from quality of care to quality of life. |
| Q38625435 | Thalassemia 2016: Modern medicine battles an ancient disease |
| Q60934196 | The relationship between vitamin C status, the gut-liver axis, and metabolic syndrome |
| Q64982592 | Thyroid Disorders in Homozygous β-Thalassemia: Current Knowledge, Emerging Issues and Open Problems. |
| Q58713260 | Validation of a standardized MRI method for liver fat and T2* quantification |
Search more.